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A number of intravenous immunoglobulin preparations are stabilized with sugar additives that may lead
over time to undesirable glycation reactions especially in liquid formulation. This study aimed to evaluate
the reactivity of sugar excipients on such preparations in condition of temperature, formulation and con-
centration commonly used for pharmaceutical products. Through an innovative LC-MS method reported
to characterize post-translational modifications of IgGs Fc/2 fragments, a stability study of IVIg formu-
lated with reducing and non-reducing sugars has been undertaken. The rate of polyclonal IgGs glycation
was investigated during 6 months at 5, 25, 30 and 40 C. High levels of glycation were observed with
reducing sugars such as glucose and maltose in the first months of the stability study from 25 C. Non-
reducing sugars presented a low reactivity even at the highest tested temperature (40 C).
Furthermore, a site by site analysis was performed by MS/MS to determine the glycation sites which were
mainly identified at Lys246, Lys248 and Lys324. This work points out the high probability of glycation reac-
tions in some commercialized products and describes a useful method to characterize IVIg glycated prod-
ucts issued from reducing sugar excipients.
 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Intravenous immunoglobulin (IVIg) preparations are mainly
composed of polyclonal immunoglobulin G (IgGs); these products
are purified from plasma and used to treat a number of humoral
immune deficiencies associated with recurrent infections and an
increasing number of autoimmune disorders. New generation of
these therapeutics is presented in a liquid formulation that is more
easy-to-use than freeze-dried products. Worldwide marketed IVIg
preparations are largely stabilized by sugars excipients [1] (see
Supplementary Table 1), which can lead over time to undesirable
glycation reactions. Glycation is a non-enzymatic process in which
reducing sugars are covalently attached to proteins by a condensa-
tion reaction between the aldehyde groups of reducing sugars and
primary or secondary amines of amino acids. The reaction results
in the formation of an unstable, reversible Schiff base intermediate
(aldimine), which may undergo an Amadori rearrangement to form
a stable ketoamine (the Amadori product). This reaction ofglycation may affect protein structure and function, and may lead
to the formation of advanced glycation end products (AGEs) [2].
Glycation of monoclonal IgGs has been investigated in several
studies. Glycation reactions were shown to occur during the up-
stream production process due to the presence of feeding sugars
and reactivity was shown to be antibody dependent [3]. Stability
studies of monoclonal IgGs long-term stored at 2–8 C in the pres-
ence of sucrose revealed non-significant glycation while this mod-
ification was observed at room temperature with dextrose [4].
Glycation of polyclonal IgGs is far less documented, perhaps
because of the analytical complexity inherent to these heteroge-
neous proteins, limiting the use of mass spectrometry. Vrdoljak
et al. reported the use of radioactive D-[U-14C]-glucose to monitor
in vitro glycation of polyclonal IgGs under pseudo-physiological/
diabetic conditions [5]. As expected, they found more glycation
of IgGs under pseudo-diabetic conditions than under pseudo-
physiological ones. They also found that glycation can occur under
long-term storage at 4–8 C, in the presence of glucose. In 2014, a
LC-MS method has been reported to investigate post-translational
modifications on the constant fragment (Fc/2) of polyclonal IgGs,
generated after IdeS enzymatic proteolysis [6]. Considering the
non-enzymatic nature of glycation reactions, glycation sites could
be distributed all over the protein sequence. Therefore, the
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clonal IgGs by LCMS, was considered as a reliable marker of the
overall IVIg glycation state.
In this study, the formulation of a 5% IVIg product was modified
in order to generate different formulations in which the stabilizing
sugar was the only variable excipient. Two reducing sugars
(maltose and glucose) and two non-reducing sugars (sucrose and
trehalose) were used to generate 4 formulations and the glycation
level of such formulated IgGs was monitored by LC-MS for
6 months at different temperatures commonly used for stability
studies (5, 25, 30 and 40 C according to ICHQ1A guideline). For
the first time, the differential reactivity of sugars on polyclonal
IgGs, i.e. the glycation rate, was studied using storage tempera-
tures, formulation and concentration test parameters, chosen to
be representative of real life conditions and usages of IVIg.2. Material and methods
2.1. Material
MS grade bovine trypsin was obtained from Roche (Mannheim,
Germany). The IdeS endoprotease FabRICATOR and the IgGZERO
glycosidase were obtained from Genovis (Lund, Sweden). Dithio-
threitol (DTT), Iodoacetamide (IAA), Glucose, Trehalose, Maltose
and Sucrose were obtained from Sigma–Aldrich (Saint Quentin Fal-
lavier, France). Acetonitrile (MeCN) was HPLC reagent grade and
purchased from JT Baker (Philipsburg, NJ, USA). Trifluoroacetic acid
(TFA) was obtained fromMerck Biosciences (Darmstadt, Germany).
All the aqueous solutions were prepared using ultra-pure water
(18.2 MX cm resistivity at 25 C, total organic carbon (TOC) <
5 ppb).
2.2. IgGs formulation and storage
Polyclonal IgGs derived from human plasma (purification based
on ethanolic and caprylic acid precipitations) were used to gener-
ate 5% liquid IVIg preparations, buffered at pH 6 with sodium
hydroxide, in the presence of either 10% w/v maltose, sucrose, tre-
halose and 5.3% w/v glucose corresponding to an equivalent molar
concentration of 292 mM for all sugars. All samples were sterile fil-
tered in laminar flow hood, aliquoted for each time point in 1.5 ml
glass vials (1 ml/vial) and stored at 5, 25, 30 and 40 C for a
6 months stability study. The climatic chambers used during the
stability were qualified and temperature controlled.
2.3. IgG enzymatic digestion and reduction
5% liquid IVIg preparations were diluted with ultra-pure water
to an IgGs final concentration of 10 g/l. Enzymatic proteolysis and
deglycosylation of IgGs were carried out by simultaneously incu-
bating 10 ll of samples during 1 h at 37 C with 100 UI of IdeS
enzyme to generate Fc/2 fragments and 100 UI of IgGZero enzyme
to leave only a fucosylated GlcNAc bound to the polypeptide chain.
Reduction of digested IgG was performed by adding 35 ll of denat-
uration buffer (8 M Guanidine-HCl, Tris–HCl 0.1 M, pH 7.5) and
5 ll of a 200 mM DTT solution. The preparation was incubated at
50 C for 30 min and subsequently analyzed by LC-MS.
2.4. LC-MS analysis
Separation of the Fc/2 fragments was carried out on an Acquity
system (Waters, Milford, MA, USA) coupled to a UV detector and an
electrospray mass spectrometer (Synapt G2S, Waters, Milford, MA,
USA). 20 lg of sample was injected on a Pursuit Diphenyl
150 mm  2.0 mm column (Agilent, Santa Clara, CA, USA)equilibrated at 70 C and operated at a flow rate of 200 ll/min.
An elution gradient was applied using solvent A (0.1% TFA in water)
and solvent B (90% MeCN, 10% water and 0.1% TFA), and after an
isocratic elution at 10% B for 5 min, B was raised to 38% in
10 min and to 44% in an additional 48 min. The column was then
washed for 4 min at 80% of B and further equilibrated during
9 min at 10% B. The mass spectrometer was operated in the posi-
tive resolution mode and data were recorded from m/z 500 to
3000. Protein mass spectra were deconvoluted using the MassLynx
software. The capability of the method was addressed by a tripli-
cate analysis of seven samples presenting glycation rates dis-
tributed over the whole range of the analytical procedure.
Coefficients of variation lower than 10% were obtained for each
point (see Supplementary Table 2).
2.5. Peptide mapping
200 lg of sample was vacuum-dried and dissolved in 25 lL of
8 M urea, and 0.2 M ammonium acetate solution pH 7.2. Reduction
was accomplished by adding 10 lL of a 200 mM DTT solution in
water and incubating the resulting mixture for 15 min at 55 C.
After cooling at room temperature, 10 lL of a 400 mM IAA solution
in water was added and the solution was incubated for 15 min in
the dark. After a fourfold dilution with water, digestion with tryp-
sin (1:10, w/w) was performed overnight at 37 C. The obtained
peptides were injected on a Waters CSH C18 column
(2.1  150 mm, 3 lm) using an Acquity system coupled to an elec-
trospray mass spectrometer Synapt G2-S (Waters, Milford, MA,
USA) operating in the positive ion mode. The spray voltage and
the source temperature were set at 3 kV and 80 C, respectively.
MS/MS data were acquired with the instrument operating in the
data-dependent mode.3. Results and discussion
3.1. Characterization of glycated Fc/2
Glycation of polyclonal IgGs was monitored by LC-MS for each
temperature on a monthly period. Mass spectrometry provides
enough resolution to observe the covalent addition of one or sev-
eral sugars, under their aldimine or ketoamine forms, to the Fc/2
protein backbone. Reversible aldimine content can be influenced
by sample preparation but in the time window of the present study
(over 6 months), stable ketoamines contribute mostly to the total
glycation content [7]. This MS based method is thus well designed
to follow the total glycation state of IVIg during monthly stabilities.
Fig. 1 shows examples of deconvoluted mass spectra obtained for
the IgG1 subclass from two distinct formulations, respectively with
maltose (A) and glucose (B) and stored during 3 months at 25 C.
Masses of 24,140 Da and 24,108 Da correspond to the Fc/2 frag-
ments of allotypes G1m3 and G1m1, 17 respectively. The mass
spectrum of Fig. 1A shows uniform mass additions of +324 Da cor-
responding to the covalent attachment of the disaccharide and the
mass spectrum of Fig. 1B shows uniformmass additions of +162 Da
in keeping with the covalent attachment of the reducing monosac-
charide. The method is thus fully suitable for the monitoring of gly-
cation due to reducing sugars directly available in the formulation
or indirectly through hydrolysis of non-reducing sugars (sucrose or
trehalose) into their reducing components.
3.2. Identification of glycated sites
Peptide mapping was used to identify the glycated sites
detected after 1 month stability at 40 C in the presence of glucose
or maltose. Three major sites were detected on the Fc/2 of
Fig. 1. IgG1 Fc/2 deconvoluted mass spectra of IVIg formulated with maltose (A) and glucose (B) stored 3 months at 25 C. Inserts represent Fc/2 chromatograms.
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spectra of the two identified peptides carrying the abovemen-
tioned glycation sites. Fig. 2A shows the MS/MS mass spectrum
of [Gly237–Arg255] peptide. The sequence of the peptide is widely
covered by y ions and, interestingly, y9 fragments are observed
as a mixture of naked, pyrylium and furylium ions, the latter being
characteristics of the dissociation pathway of aldohexoses-derived
Amadori compounds [8]. After y10 all the fragments were identified
as pyrylium and furylium ions exclusively which indicates that the
selected precursor ion corresponds to a mixture of glycated species
at both Lys246 and Lys248 positions. It can be noticed that this pre-
cursor ion gave a single chromatographic peak in spite of its struc-
tural heterogeneity. Fig. 2B shows the MS/MS mass spectrum of
[Cys319–Lys332] peptide. Fragments b7 to b10 and y11 to y13 were
identified as pyrylium and furylium ions, indicating a glycated site
at Lys324 position. Finally, these glycation sites were found to be
consistent with those already described in the literature for mon-
oclonal antibodies [7]. Other minor glycation sites (in terms of pep-
tide intensity) were also detected on the CH1 domain of IgGs, on
Lys143 residue of the heavy chain and on Lys126 and Lys149 residues
of the light chain (data not shown).
3.3. Kinetics of IVIg glycation
To monitor glycation, an LC-MS analysis was performed for each
temperature, formulation and time point. The peak intensities of
the deconvoluted mass spectra were used to determine a percent-
age of glycated versus non-glycated IgGs. Assuming a similar MSresponse factor for all the detected species, glycated IgGs were
defined as the sum of forms detected with at least one glycation
adduct over the total signal. Fig. 3 reviews data collected at 25 C
for the 4 formulations. Surprisingly, formulations using reducing
sugars show a high degree of glycation over time at a widely used
storage temperature (see Fig. 3A and B) with up to 3 binding sugars
detected per Fc/2. On the contrary, glycation is not observed even
after 6 months at 25 C with formulations based on sucrose and
trehalose excipients (see Fig. 3C and D). Fig. 4 provides a summary
of all the data collected during the study. Analysis of samples at T0
revealed a residual glycation rate of approximatively 2.7%, reflect-
ing probably an in vivo baseline glycation level. After 1 month at
5 C, 25 C, 30 C and 40 C, respectively 3.9%, 22.3%, 37.1% and
85.9% of IgGs Fc/2 were glycated with the glucose excipient, and
these values increased to 8.3%, 76.8%, 91.8% and 100% after
6 months. The rate of glycation increased with temperature and
followed perfectly the Arrhenius law with a straight line observed
by plotting the logarithm of the glycation percentage against inverse
temperature (see kinetic rates of glycation in Supplementary
Table 3). Furthermore, for each temperature, the time dependence
of glycation fitted well a first order kinetic reaction, as expected
for the Maillard reaction. At all points, the reactivity of glucose
was slightly greater than the one of maltose. This difference of reac-
tivity between glucose and maltose is consistent with the overall
knowledge of the Maillard reaction. Indeed, the reactivity of the
reducing sugars depends on their size, pentoses being more reactive
than hexoses and hexoses like glucose being more reactive than dis-
accharides like maltose. It can be noticed that only highly glycated
Fig. 2. MS/MS spectra of peptide [Gly237–Arg255] glycated on Lys246 or Lys248 (panel A) and peptide [Cys319–Lys332] glycated on Lys324 (panel B) from IgGs formulated with
maltose and stored 1 month at 40 C.
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higher content of aggregates (see Supplementary Table 4). Interest-
ingly, even at the temperature of 5 C, a slight increase of glycation is
observed over time with glucose and maltose suggesting that even
this low storage temperature is not a guarantee of preventing glyca-
tion when reducing sugars are used as excipients. This result is in
keeping with Vrdoljak et al. [5], reporting IgG glycation after long
term storage at 4–8 C in the presence of glucose. Instead, formula-
tions based on sucrose and trehalose excipients were relatively
stable. No glycation reactions were observed with trehalose even
at the highest temperature and the last time point of the stability
study. However, with the sucrose excipient, a detectable increase
of glycation was observed after 4 months at 40 C (9.6%) and con-firmed with latter time points (18.3% after 6 months storage). The
glycation observed with sucrose (adding of a single monosaccharide
of +162 Da) is probably the result of an initial hydrolysis of the non-
reducing sugar that releases reducing glucose in the media. This
result confirms data from the food industry indicating that trehalose
is more stable than sucrose.
Glycation is an undesirable reaction that binds covalently sugar
molecules on primary/secondary amine functions distributed all
over the protein sequence. This kind of reaction modifies perma-
nently the physicochemical properties of proteins and may induce
changes of conformation, stability and activity [9]. Uncontrolled
high blood sugar concentration leads to glycation of blood proteins
and to various diabetes complications. Vrdoljak et al. [5] estimated
Fig. 3. IgG1 Fc/2 deconvoluted mass spectra of samples formulated with maltose (A), glucose (B), sucrose (C) and trehalose (D) stored from 0 to 6 months at 25 C.
Y. Leblanc et al. / European Journal of Pharmaceutics and Biopharmaceutics 102 (2016) 185–190 189in vitro, by the use of radioactive D-[U-14C]-glucose, the number of
glucose molecules bound per IgG to an average of 3.1 after incuba-
tion with glucose in the concentration characteristic for diabetics.
In another study, Lapolla et al. [10] ranged from 7 to 28 the number
of glucose units condensed on IgGs from badly controlled diabetic
patients, using MALDI-MS. The present LC-MS method has the
advantage to visually observe the addition of single glucose units
to the Fc/2 of IgGs and our data indicate that IVIg products stored
with reducing sugars at 25 and 30 C can reach the same range of
glucose addition as diabetics. Kennedy et al. have shown that gly-
cation could restrain the binding of IgGs to their antigens and
increase their clearance rate in mice [11]. An increase in perme-
ability of glycated proteins across the blood-nerve barrier has been
observed from patients with diabetic polyneuropathy [12] and
Brownlee et al. [13] demonstrated a clear increase of trapped
IgM and IgG in peripheral nerve myelin from diabetics which has
been suggested to have detrimental effects on nerve functions.
These reports raise the hypothesis of a possible relationship
between the glycation status of pharmaceutical products and their
tolerability.4. Conclusion
Sugars are widely used by pharmaceutical companies for the
stabilization of highly concentrated proteins, but to our knowl-
edge, the glycation state of IVIg in pharmaceutical conditions ofstability has never been documented so far. This work investigates
sugar excipients reactivity on IVIg and describes a MS-based
method that is appropriate to monitor routinely the glycation sta-
tus of IVIg as it is required for monoclonal antibodies (EMEA/
CHMP/BWP/157653/2007). Reducing sugar excipients currently
used for commercialized products generate significant glycation
reactions from 25 C in a time frame as short as 6 months. The
reaction follows the Arrhenius law; as a consequence the glycation
effect is minimized at 5 C but not abolished. The use of non-
reducing sugars such as trehalose and sucrose was more successful
to avoid glycation. Considering that some commercialized IVIg
preparations are formulated with reducing sugars in liquid state
[1], our results support strong evidence that glycation reactions
are highly probable for these products and that the present LC-
MS method is adequate to assess this criteria for the different
claimed storage temperatures. As mentioned above, glycation of
proteins may alter their physicochemical and biological properties.
This study raises the question of possible tolerability issues in rela-
tion with the use of reducing sugars especially in the case of
chronic impregnation with IVIg.Conflict of interest
All authors are employees of LFB BIOTECHNOLOGIES or LFB BIO-
MEDICAMENTS, subsidiaries of LFB SA group, and commercializing
IVIg preparations.
Fig. 4. Time course of Fc/2 glycation of IgGs stored at 5 C, 25 C, 30 C and 40 C and formulated with glucose (j), maltose (d), sucrose (▲) and trehalose (.).
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